Next Generation cancer 'omics technologies are revolutionizing our understanding of cancer, but our approaches to clinical investigation have not kept pace. The Cancer Genome Atlas (TCGA) is delivering an impressive body of data and technical advances in data analysis, but is analytically limited by the uncontrolled clinical settings in which the samples were accrued. We therefore propose to match the technical expertise of The Genome Institute at Washington University with the accrual power and clinical expertise of the NRG cooperative group to provide clinical and biological annotation for the vast quantities of new data generated by high-throughput sequencing platforms. We also anticipate major technical advances in the proteomics field as a result of the investment by the NCI in the Clinical Proteomics Tumor Analysis Consortium (CPTAC). We therefore propose the """"""""Integrated Translational Genoproteomlcs Center"""""""" (ITGC) that will nucleate a concerted effort to integrate DNA, RNA and Peptide sequencing into NRG clinical trials to a) increase our biological understanding of common epithelial cancers, b) develop biomarkers of treatment response and c) identify new therapeutic targets. This proposal includes plans for five proteogenomic pilot projects with NRG Oncology In breast cancer, head and neck cancer, ovarian cancer, rectal cancer and prostate cancer.
The aims of these demonstration projects are to fully integrate proteogenomics into prospective clinical trials of preoperative systemic therapy, to develop genoproteomic assays for clinical trial eligibility and stratification and to integrate mass-spectrometry-based and reverse phase protein array-based (RPPA) proteomics into the existing genomic sample analysis pipeline. Our strategic objective is to bring comprehensive discovery science into the cooperative group setting. This will drive the NRG Oncology organ site committees to more deeply appreciate the fundamental biology that underlies the diseases that they treat and should ultimately raise the quality of the clinical trial hypotheses that are pursue.

Public Health Relevance

The integration of DNA, RNA and Peptide sequencing-based discovery science into cooperative group trials is our goal. This will stimulate biomarker research that will drive te development of laboratory tests required for our long-term goal of a tumor etiology-matched therapeutics program that improves outcomes for a broad spectum of patients diagnosed with common epithelial malignancies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O1))
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Internal Medicine/Medicine
Schools of Medicine
Saint Louis
United States
Zip Code
Eisfeld, A-K; Mrózek, K; Kohlschmidt, J et al. (2017) The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia 31:2211-2218
Luo, Jingqin; Liu, Shuzhen; Leung, Samuel et al. (2017) An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors. J Mol Diagn 19:147-161
Luo, Jingqin; D'Angela, Gina; Gao, Feng et al. (2015) Bivariate correlation coefficients in family-type clustered studies. Biom J 57:1084-109
Witek, Matthew; Vahknenko, Yelena; Siglin, Joshua et al. (2014) Dose Reduction to the Scalp with Hippocampal Sparing Is Achievable with Intensity Modulated Radiotherapy. Int J Med Phys Clin Eng Radiat Oncol 3:176-182